NewAmsterdam Pharma N.V. (NAMS)
NewAmsterdam Pharma Statistics
Share Statistics
NewAmsterdam Pharma has 109.82M shares outstanding. The number of shares has increased by 19.68% in one year.
| Shares Outstanding | 109.82M |
| Shares Change (YoY) | 19.68% |
| Shares Change (QoQ) | 18.68% |
| Owned by Institutions (%) | 99.99% |
| Shares Floating | 58.1M |
| Failed to Deliver (FTD) Shares | 20 |
| FTD / Avg. Volume | < 0.01% |
Short Selling Information
The latest short interest is 2.99M, so 2.8% of the outstanding shares have been sold short.
| Short Interest | 2.99M |
| Short % of Shares Out | 2.8% |
| Short % of Float | 4.94% |
| Short Ratio (days to cover) | 4.69 |
Valuation Ratios
The PE ratio is -10.04 and the forward PE ratio is -12.31. NewAmsterdam Pharma's PEG ratio is -0.53.
| PE Ratio | -10.04 |
| Forward PE | -12.31 |
| PS Ratio | 53.22 |
| Forward PS | 3.4 |
| PB Ratio | 3.2 |
| P/FCF Ratio | -15.23 |
| PEG Ratio | -0.53 |
Enterprise Valuation
NewAmsterdam Pharma N.V. has an Enterprise Value (EV) of 577.36M.
| EV / Earnings | -2.39 |
| EV / Sales | 12.67 |
| EV / EBITDA | -2.39 |
| EV / EBIT | -3.28 |
| EV / FCF | -3.63 |
Financial Position
The company has a current ratio of 8.08, with a Debt / Equity ratio of 0.
| Current Ratio | 8.08 |
| Quick Ratio | 8.08 |
| Debt / Equity | 0 |
| Total Debt / Capitalization | 0.06 |
| Cash Flow / Debt | -353.94 |
| Interest Coverage | 0 |
Financial Efficiency
Return on equity (ROE) is -0.32% and return on capital (ROIC) is -23.26%.
| Return on Equity (ROE) | -0.32% |
| Return on Assets (ROA) | -0.28% |
| Return on Capital (ROIC) | -23.26% |
| Revenue Per Employee | $670,044.12 |
| Profits Per Employee | $-3,552,911.76 |
| Employee Count | 68 |
| Asset Turnover | 0.05 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | -1K |
| Effective Tax Rate | 0 |
Stock Price Statistics
The stock price has increased by -7.95% in the last 52 weeks. The beta is -0.04, so NewAmsterdam Pharma's price volatility has been lower than the market average.
| Beta | -0.04 |
| 52-Week Price Change | -7.95% |
| 50-Day Moving Average | 21.73 |
| 200-Day Moving Average | 20.13 |
| Relative Strength Index (RSI) | 43.73 |
| Average Volume (20 Days) | 877.49K |
Income Statement
In the last 12 months, NewAmsterdam Pharma had revenue of 45.56M and earned -241.6M in profits. Earnings per share was -2.56.
| Revenue | 45.56M |
| Gross Profit | 45.56M |
| Operating Income | -176.29M |
| Net Income | -241.6M |
| EBITDA | -241.49M |
| EBIT | -176.29M |
| Earnings Per Share (EPS) | -2.56 |
Balance Sheet
The company has 771.74M in cash and 448K in debt, giving a net cash position of 771.29M.
| Cash & Cash Equivalents | 771.74M |
| Total Debt | 448K |
| Net Cash | 771.29M |
| Retained Earnings | 0 |
| Total Assets | 864.62M |
| Working Capital | 756.5M |
Cash Flow
In the last 12 months, operating cash flow was -158.56M and capital expenditures -672K, giving a free cash flow of -159.24M.
| Operating Cash Flow | -158.56M |
| Capital Expenditures | -672K |
| Free Cash Flow | -159.24M |
| FCF Per Share | -1.69 |
Margins
Gross margin is 100%, with operating and profit margins of -386.91% and -530.25%.
| Gross Margin | 100% |
| Operating Margin | -386.91% |
| Pretax Margin | -530.25% |
| Profit Margin | -530.25% |
| EBITDA Margin | -530% |
| EBIT Margin | -386.91% |
| FCF Margin | -349.49% |
Dividends & Yields
NAMS does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | -11.76% |
| FCF Yield | -6.66% |
Analyst Forecast
The average price target for NAMS is $42, which is 92.9% higher than the current price. The consensus rating is "Buy".
| Price Target | $42 |
| Price Target Difference | 92.9% |
| Analyst Consensus | Buy |
| Analyst Count | 6 |
Scores
| Altman Z-Score | 13.96 |
| Piotroski F-Score | 3 |